Cargando…

The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation

In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfonsi, Romina, Grassi, Ludovica, Signore, Michele, Bonci, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979514/
https://www.ncbi.nlm.nih.gov/pubmed/29652798
http://dx.doi.org/10.3390/ijms19041183
_version_ 1783327714973843456
author Alfonsi, Romina
Grassi, Ludovica
Signore, Michele
Bonci, Désirée
author_facet Alfonsi, Romina
Grassi, Ludovica
Signore, Michele
Bonci, Désirée
author_sort Alfonsi, Romina
collection PubMed
description In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy.
format Online
Article
Text
id pubmed-5979514
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59795142018-06-10 The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation Alfonsi, Romina Grassi, Ludovica Signore, Michele Bonci, Désirée Int J Mol Sci Review In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy. MDPI 2018-04-13 /pmc/articles/PMC5979514/ /pubmed/29652798 http://dx.doi.org/10.3390/ijms19041183 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alfonsi, Romina
Grassi, Ludovica
Signore, Michele
Bonci, Désirée
The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title_full The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title_fullStr The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title_full_unstemmed The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title_short The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation
title_sort double face of exosome-carried micrornas in cancer immunomodulation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979514/
https://www.ncbi.nlm.nih.gov/pubmed/29652798
http://dx.doi.org/10.3390/ijms19041183
work_keys_str_mv AT alfonsiromina thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT grassiludovica thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT signoremichele thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT boncidesiree thedoublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT alfonsiromina doublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT grassiludovica doublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT signoremichele doublefaceofexosomecarriedmicrornasincancerimmunomodulation
AT boncidesiree doublefaceofexosomecarriedmicrornasincancerimmunomodulation